TrimMedium
AURA remains in a confirmed Stage 4 decline with a negative EMA regime and persistent lower highs/lows. Medium‐term bias is bearish, but price is now oversold and extended below key EMAs. We defer selling until relief rallies into the 9/21 EMA & 50 SMA zone for rejection‐based trimming.
- ↑Phase 2 AU-011 trial showed positive end-of-study efficacy in early-stage choroidal melanoma, driving a potential FDA filing catalyst
- ↑Phase 1 NMIBC results indicated strong biological activity and immune response, expanding commercial opportunity
- ↓Negative earnings yield and poor profitability metrics highlight inability to generate returns
Full analysis →
